Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 1,990,000 shares, a decline of 9.1% from the February 13th total of 2,190,000 shares. Currently, 3.6% of the company’s stock are short sold. Based on an average daily volume of 381,800 shares, the short-interest ratio is presently 5.2 days.
Analyst Ratings Changes
A number of research analysts recently issued reports on the company. Citigroup increased their price objective on Aldeyra Therapeutics from $23.00 to $28.00 in a report on Friday, March 10th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Aldeyra Therapeutics in a research note on Friday, March 10th.
Institutional Trading of Aldeyra Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC raised its holdings in shares of Aldeyra Therapeutics by 14.6% in the 3rd quarter. Perceptive Advisors LLC now owns 11,350,085 shares of the biotechnology company’s stock valued at $60,609,000 after purchasing an additional 1,446,206 shares during the period. Vanguard Group Inc. lifted its position in shares of Aldeyra Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 2,961,635 shares of the biotechnology company’s stock valued at $13,165,000 after buying an additional 147,711 shares during the last quarter. Verition Fund Management LLC boosted its stake in shares of Aldeyra Therapeutics by 26.4% during the 3rd quarter. Verition Fund Management LLC now owns 2,402,239 shares of the biotechnology company’s stock worth $12,828,000 after acquiring an additional 501,048 shares during the period. Prosight Management LP increased its holdings in shares of Aldeyra Therapeutics by 41.8% during the 2nd quarter. Prosight Management LP now owns 1,985,883 shares of the biotechnology company’s stock worth $7,924,000 after acquiring an additional 585,644 shares during the last quarter. Finally, Knoll Capital Management LLC raised its stake in Aldeyra Therapeutics by 24.9% in the 3rd quarter. Knoll Capital Management LLC now owns 1,877,305 shares of the biotechnology company’s stock valued at $10,025,000 after acquiring an additional 374,845 shares during the period. Institutional investors and hedge funds own 63.11% of the company’s stock.
Aldeyra Therapeutics Stock Up 12.0 %
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
- Get a free copy of the StockNews.com research report on Aldeyra Therapeutics (ALDX)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.